Everything below concerns REV-ERB agonist. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
The prothrombin time (PT) – along with its derived measures of prothrombin ratio (PR) and international normalized ratio (INR) – is an assay for evaluating the extrinsic pathway and common pathway of coagulation. This blood test is also called protime INR and PT/INR. They are used to determine the clotting tendency of blood, in conditions such as the measure of warfarin dosage, liver damage (cirrhosis), and vitamin K status. PT measures the following coagulation factors: I (fibrinogen), II (prothrombin), V (proaccelerin), VII (proconvertin), and X (Stuart–Prower factor). PT is often used in conjunction with the activated partial thromboplastin time (aPTT) which measures the intrinsic pathway and common pathway of coagulation.
In June 1789, the regiment was formed in England as a permanent unit to relieve the New South Wales Marine Corps, who had accompanied the First Fleet to Australia. The regiment began arriving as guards on the Second Fleet in 1790. The regiment, led by Major Francis Grose, consisted of three companies, numbering about 300 men. Although drafts were sent from Britain to reinforce the regiment throughout its time in Australia, its full strength never exceeded 500. A fourth company was raised from those Marines wishing to remain in New South Wales under Captain George Johnston, who had been Governor Arthur Phillip's aide-de-camp. In December 1792, when Phillip returned to England for respite, Grose was left in charge. Grose immediately abandoned Phillip's plans for governing the colony. A staunch military man, he established military rule and set out to secure the authority of the Corps. He abolished the civilian courts and transferred the magistrates to the authority of Captain Joseph Foveaux. After the poor crops of 1793 he cut the rations of the convicts but not those of the Corps, overturning Phillip's policy of equal rations for all. In a connived attempt to improve agricultural production and make the colony more self-sufficient, Grose turned away from collective farming and made generous land grants to officers of the Corps. They were also provided with government-fed and clothed convicts as farm labour.
Rather, the tRNA-bound seryl residue is converted to a selenocysteine residue by the pyridoxal phosphate-containing enzyme selenocysteine synthase. In eukaryotes and archaea, two enzymes are required to convert tRNA-bound seryl residue into tRNA selenocysteinyl residue: PSTK (O-phosphoseryl-tRNA[Ser]Sec kinase) and selenocysteine synthase. Finally, the resulting Sec-tRNASecis specifically bound to an alternative translational elongation factor (SelB or mSelB (or eEFSec)), which delivers it in a targeted manner to the ribosomes translating mRNAs for selenoproteins. The specificity of this delivery mechanism is brought about by the presence of an extra protein domain (in bacteria, SelB) or an extra subunit (SBP2 for eukaryotic mSelB/eEFSec) which bind to the corresponding RNA secondary structures formed by the SECIS elements in selenoprotein mRNAs.
=== Matrix === The matrix system has a drug layer of a semisolid matrix containing a drug solution or suspension. The adhesive layer in this patch surrounds the drug layer, partially overlaying it. The release rate is determined by the physical properties of the matrix. Also known as a monolithic device. Limited research indicates that it may be possible to cut some matrix patches to provide lower doses, provided the cut part not immediately used is stored at cool temperatures.
Sources: en.wikipedia.org
In Chennai, Tamil Nadu CMDA authorities placed a seal on the massive warehouse spreading across 7 acres that had reportedly been built for one of the world's leading multinational retail giants, Wal-mart. Domestic retail players like Future Retail, Avenues Supermarket and Aditya Birla Fashion and Retail has been slowly growing, making entering the country more difficult for MNCs like Walmart and Carrefour. On 28 August 2019, Indian union cabinet approved proposals to ease local sourcing norms as applicable to SBRT.
Belize has a tropical climate with pronounced wet and dry seasons, although there are significant variations in weather patterns by region. Temperatures vary according to elevation, proximity to the coast, and the moderating effects of the northeast trade winds off the Caribbean. Average temperatures in the coastal regions range from 24 °C (75.2 °F) in January to 27 °C (80.6 °F) in July. Temperatures are slightly higher inland, except for the southern highland plateaus, such as the Mountain Pine Ridge, where it is noticeably cooler year round. Overall, the seasons are marked more by differences in humidity and rainfall than in temperature. Average rainfall varies considerably, from 1,350 millimetres (53 in) in the north and west to over 4,500 millimetres (180 in) in the extreme south. Seasonal differences in rainfall are greatest in the northern and central regions of the country where, between January and April or May, less than 100 millimetres (3.9 in) of rainfall per month. The dry season is shorter in the south, normally only lasting from February to April. A shorter, less rainy period, known locally as the "little dry", usually occurs in late July or August, after the onset of the rainy season. Hurricanes Hurricanes have played key—and devastating—roles in Belizean history. In 1931, an unnamed hurricane destroyed over two-thirds of the buildings in Belize City and killed more than 1,000 people. In 1955, Hurricane Janet levelled the northern town of Corozal.
Inflammatory arthritides such as ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis and systemic lupus erythematosus can all cause varying levels of joint destruction. Among the inflammatory arthritides, ankylosing spondylitis is most closely associated with back pain because of the inflammatory destruction of the bony components of the spine. Ankylosing spondylitis is common in young men and presents with a range of possible symptoms such as uveitis, psoriasis and inflammatory bowel disease.
RCO2H + R'2NH → RCO−2 + R'2NH+2 RCO−2 + R'2NH+2 → RC(O)NR'2 + H2O Esters are far superior substrates relative to carboxylic acids. Further "activating" both acid chlorides (Schotten-Baumann reaction) and anhydrides (Lumière–Barbier method) react with amines to give amides:
== History == Nalbuphine was first synthesized in 1965 and was introduced for medical use in the United States in 1979. In the search for opioid analgesics with less abuse potential than pure MOR agonist opioids, a number of semisynthetic opioids were developed. These substances are referred to as mixed agonist–antagonists analgesics. Nalbuphine belongs to this group of substances. The mixed agonists-antagonists drug class exerts their analgesic actions by agonistic activity at the KOR. While all drugs in this class possess MOR antagonistic activity leading to less abuse potential, nalbuphine is the only approved drug in the mixed agonist–antagonist class listed in terms of its pharmacological actions and selectivities on opioid receptors as a MOR partial agonist or antagonist as well as a KOR agonist (Gustein et al. 2001). Nubain was approved for marketing in the United States in 1978 and remains as the only opioid analgesic of this type (marketed in the U.S.) not controlled under the Controlled Substances Act (CSA). When the Controlled Substances Act (CSA) was enacted in 1971, nalbuphine was placed in schedule II. Endo Laboratories, Inc. subsequently petitioned the DEA to exclude nalbuphine from all schedules of the CSA in 1973. After receiving a medical and scientific review and a scheduling recommendation from the Department of Health, Education and Welfare, forerunner to the Department of Health and Human Services, nalbuphine was removed from schedule II of the CSA in 1976. Presently, nalbuphine is not a controlled substance under the CSA.
Sources: en.wikipedia.org
A G cell or gastrin cell is a type of cell in the stomach and duodenum that secretes gastrin. It works in conjunction with gastric chief cells and parietal cells. G cells are found deep within the pyloric glands of the stomach antrum, and occasionally in the pancreas and duodenum. The vagus nerve innervates the G cells. Gastrin-releasing peptide is released by the post-ganglionic fibers of the vagus nerve onto G cells during parasympathetic stimulation. The peptide hormone bombesin also stimulates gastrin from G cells. Gastrin-releasing peptide, as well as the presence of amino acids in the stomach, stimulates the release of gastrin from the G cells. Gastrin stimulates enterochromaffin-like cells to secrete histamine. Gastrin also targets parietal cells by increasing the amount of histamine and the direct stimulation by gastrin, causing the parietal cells to increase HCl secretion in the stomach. G-cells frequently express PD-L1 during homeostasis which protects them from Helicobacter pylori-induced immune destruction.
=== Durability === Mid-term durability from ESG appears promising. A total body weight loss of 17% and excess weight loss of between approximately 60-67% was observed to be sustained at 18–24 months. This was later confirmed in the multicenter, randomized controlled MERIT study, which observed that 68% of subjects who underwent an ESG maintained 25% or more of their excess weight loss at two years. As a novel therapy, ESG presently lacks studies assessing long-term durability, though more data on this component of ESG are anticipated as more ESGs are performed over time. One recent study observed at 5 years from ESG that at least 10% total body weight loss was maintained in 90% of patients and at least 15% total body weight loss was maintained in 61% of patients.
== External links == Finding Aid to The Dr. Michael Somogyi Collection, 1912–1979 (bulk 1924–1970) at the Science History Institute (For full finding aid, click on 'Dr. Michael Somogyi Collection Finding Aid'.) Finding Aid to Photographs from the Dr. Michael Somogyi Collection, 1912–1971 (bulk 1950s) at the Science History Institute (For full finding aid, click on 'Dr. Michael Somogyi Collection Finding Aid'.)
According to his notes, Cushing visited her next about a week later on February 13, at which point the bill was paid and he declared that she was in a "normal condition." The next day she sent a letter to Julius Dresser, a fellow student of Quimby and future critic of Eddy, telling him that she had fallen on the sidewalk, was "taken up for dead, came to consciousness... but to find [herself] the helpless cripple [she] was before [she] saw Dr. Quimby." She further stated that despite the physician's predictions, she had gotten out of bed and walked by herself; but now she was frightened and wanted Dresser's help. On March 2, Dresser sent a letter declining her request, suggesting she could do more for herself than he could, and refusing to step into Quimby's shoes as a healer. Eddy's letter was later used by Milmine to accuse Eddy of basically making up the whole thing, saying that in asking Dresser for help, it showed she had not fully recovered. Huge Studdert Kennedy writes that her asking for help may have been occasioned by her fear of previous experiences with relapses from physical difficulties, particularly under Quimby's treatment. Milmine's critical McClure's biography also claimed that she wasn't really injured much or at all to begin with; in 1908 they solicited an affidavit from Cushing in which he stated he never took Eddy's injury to be serious, and never heard anything about a miraculous cure. He also stated that it was he, and not God, that cured her.
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.